Compounds of formula (I):

##STR00001##

wherein R.sub.a, R.sub.b, R.sub.c, R.sub.d, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Provision of orally-available and low-toxic somatostatin receptor subtype 2 agonist. Since the compound represented by the general formula (I): ##STR00001##
[wherein all symbols represent the same meanings as those described in the description] a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof is non-peptidic low-molecular compound which has strong somatostatin receptor subtype 2 agonist activity, the compound is orally-available. Additionally, since the compound is low-toxic, the compound is useful for the prevention and/or treatment of the somatostatin related diseases such as acromegaly or gastrointestinal obstruction.

Compounds of formula (I): ##STR00001##
wherein R.sub.a, R.sub.b, R.sub.c, R.sub.d, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

Compounds of formula (I): ##STR00001##
wherein R.sub.a, R.sub.b, R.sub.c, R.sub.d, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, X, Y and Het are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

This invention relates to generally inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3).